Compare LEVI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEVI | PTGX |
|---|---|---|
| Founded | 1853 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.3B |
| IPO Year | 2019 | 2016 |
| Metric | LEVI | PTGX |
|---|---|---|
| Price | $19.97 | $139.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $28.07 | ★ $174.69 |
| AVG Volume (30 Days) | ★ 1.6M | 535.2K |
| Earning Date | 10-07-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | ★ 178.85 | N/A |
| EPS | 0.67 | ★ 2.35 |
| Revenue | ★ $6,282,000,000.00 | N/A |
| Revenue This Year | $7.59 | $1,078.44 |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | ★ $29.34 | $60.03 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $62.24 |
| 52 Week High | $25.70 | $160.81 |
| Indicator | LEVI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 44.31 |
| Support Level | $19.13 | $132.37 |
| Resistance Level | $20.37 | $142.20 |
| Average True Range (ATR) | 0.43 | 4.59 |
| MACD | 0.09 | -0.44 |
| Stochastic Oscillator | 36.36 | 39.61 |
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.